Published in Medical Verdicts and Law Weekly, May 31st, 2007
This trend article is an immediate alert from NewsRx to identify the most recent news developments at Dyax Corp..
Report 1: Dyax Corp. (Nasdaq:DYAX) announced that patient treatment has begun in the Phase 3 confirmatory trial, known as EDEMA4, for its lead product candidate, DX-88 (ecallantide). DX-88, an internally discovered, recombinant, plasma kallikrein inhibitor, is in clinical trials for the treatment of acute attacks of hereditary angioedema (HAE), a rare genetic disease characterized by episodes of acute swelling and inflammation. Dyax is also initiating a Phase 2 clinical trial of...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Verdicts and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.